CA2371849A1 - Complexes constitues d'un anticorps et de chimiokines biotinylees - Google Patents

Complexes constitues d'un anticorps et de chimiokines biotinylees Download PDF

Info

Publication number
CA2371849A1
CA2371849A1 CA002371849A CA2371849A CA2371849A1 CA 2371849 A1 CA2371849 A1 CA 2371849A1 CA 002371849 A CA002371849 A CA 002371849A CA 2371849 A CA2371849 A CA 2371849A CA 2371849 A1 CA2371849 A1 CA 2371849A1
Authority
CA
Canada
Prior art keywords
biotin
composition
antibody
complex
chemokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371849A
Other languages
English (en)
Inventor
Dulce Soler
Dominic Picarella
Walter Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA2371849A1 publication Critical patent/CA2371849A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des agents actifs pharmacologiquement biotinylés, ainsi que des complexes renfermant lesdits agents. L'invention concerne, en particulier, des chimiokines biotinylées. Les complexes précités comprennent également un anticorps anti-biotine liant sélectivement la biotine. Ces complexes, qui peuvent se dissocier au contact de biotine libre, sont particulièrement utiles pour accroître la réponse immunitaire aux cellules tumorales et aux cellules infectées par virus, in vivo ou in vitro.
CA002371849A 1999-02-22 2000-02-18 Complexes constitues d'un anticorps et de chimiokines biotinylees Abandoned CA2371849A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12100699P 1999-02-22 1999-02-22
US60/121,006 1999-02-22
PCT/US2000/004312 WO2000050088A2 (fr) 1999-02-22 2000-02-18 Complexes constitues d'un anticorps et de chimiokines biotinylees

Publications (1)

Publication Number Publication Date
CA2371849A1 true CA2371849A1 (fr) 2000-08-31

Family

ID=22393879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371849A Abandoned CA2371849A1 (fr) 1999-02-22 2000-02-18 Complexes constitues d'un anticorps et de chimiokines biotinylees

Country Status (6)

Country Link
EP (1) EP1154799A2 (fr)
JP (1) JP2002537362A (fr)
AU (1) AU3370000A (fr)
CA (1) CA2371849A1 (fr)
MX (1) MXPA01008465A (fr)
WO (1) WO2000050088A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877177B2 (en) 2008-09-10 2014-11-04 Ith Immune Therapy Holdings Ab Chemokine containing apheresis column and methods of use
WO2012093068A1 (fr) * 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag Composition pharmaceutique à base d'un complexe associant un anticorps anti-dig et de la digoxigénine conjuguée à un peptide
EP2717941B1 (fr) 2011-06-13 2020-04-01 TLA Targeted Immunotherapies AB Traitement du cancer
WO2012172340A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement de troubles mentaux
CN103796693B (zh) 2011-06-13 2017-05-31 Ith免疫治疗控股股份公司 治疗与代谢综合征相关的病症
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
ES2613593T3 (es) 2011-06-13 2017-05-24 Ith Immune Therapy Holdings Ab Diagnóstico y tratamiento de enfermedad inflamatoria del intestino y síndrome del intestino irritable
ES2664836T3 (es) 2011-06-13 2018-04-23 Tla Targeted Immunotherapies Ab Tratamiento de esclerosis múltiple
WO2012172336A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement de maladies inflammatoires de la peau
WO2012172339A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement de l'arthrite inflammatoire
WO2012172344A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement d'états associés à la sepsie
WO2012172337A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement de maladie cardiovasculaire
WO2012172345A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement d'états associés à l'allergie
WO2012172343A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement de l'angiocholite sclérosante primitive
WO2012172346A2 (fr) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Traitement de maladies respiratoires
CN104411725B (zh) 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 抗生物素抗体及使用方法
RU2017128512A (ru) 2012-07-04 2019-02-15 Ф. Хоффманн-Ля Рош Аг Антитела к теофиллину и способы их применения
CN107973856B (zh) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 共价连接的抗原-抗体缀合物
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
EP3089759B1 (fr) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Conjugués covalents entre un anticorps et une toxine polypeptidique
PL3089996T3 (pl) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
RU2694981C2 (ru) 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
RU2705299C2 (ru) 2014-06-26 2019-11-06 Ф. Хоффманн-Ля Рош Аг Антитела против 5-бром-2'-дезоксиуридина и способы применения
CN110088129A (zh) * 2016-12-27 2019-08-02 豪夫迈·罗氏有限公司 新的生物素特异性单克隆抗体及其用途
KR20210126136A (ko) * 2016-12-27 2021-10-19 에프. 호프만-라 로슈 아게 신규한 비오틴-특이적 단일클론 항체 및 그 용도
EP3562841A1 (fr) * 2016-12-27 2019-11-06 H. Hoffnabb-La Roche Ag Nouvel anticorps monoclonal spécifique de la biotine, et son utilisation
CN111171154B (zh) 2020-02-25 2021-05-11 杭州百凌生物科技有限公司 一种抗生物素抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1248685B (it) * 1990-06-04 1995-01-26 Tecnogen Scpa Procedimento per la identificazione di sequenze polinucleotidiche e dispositivo relativo
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US20030171551A1 (en) * 1997-01-31 2003-09-11 Joseph D. Rosenblatt Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
WO2000012554A1 (fr) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
EP2386565A3 (fr) * 1999-01-12 2013-11-20 Cambridge Enterprise Ltd. Composés et procédés pour inhiber ou augmenter une réponse inflammatoire

Also Published As

Publication number Publication date
AU3370000A (en) 2000-09-14
WO2000050088A3 (fr) 2000-12-21
WO2000050088A2 (fr) 2000-08-31
EP1154799A2 (fr) 2001-11-21
MXPA01008465A (es) 2003-06-06
JP2002537362A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
CA2371849A1 (fr) Complexes constitues d'un anticorps et de chimiokines biotinylees
CA2172630C (fr) Proteine serique et cellulaire d'ancrage et conjugues
Von Hundelshausen et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium
JP6901493B2 (ja) 抗ｂｃｍａポリペプチド及びタンパク質
JP4255512B2 (ja) 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物
CN104039320B (zh) 血液恶性肿瘤用抗-cxcr4抗体的治疗
US6358697B2 (en) Intracellular pharmaceutical targeting
CN111630070A (zh) 三特异性蛋白质及使用方法
US20060073114A1 (en) Compounds and methods to inhibit or augment an inflammatory response
JP2000510685A (ja) 単球化学誘引タンパク質１（ｍｃｐ―１）レセプター（ｃｃｒ２）に結合する抗体
JP2010155852A (ja) リンホトキシンβ経路の遮断によるウイルス誘導性全身性ショックおよび呼吸窮迫の逆転
WO2017012591A1 (fr) Complexe comprenant une nanoparticule métallique, des séquences de liaison et des anticorps
JP2005532252A (ja) インテグリンターゲッティング化合物
AU758576C (en) Chemokines with amino-terminal modifications
NZ578635A (en) Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
US20180271997A1 (en) Methods and Reagents to Treat Tumor and Cancer
CN110520151A (zh) 胰高血糖素受体结合蛋白和其使用方法
WO2018231661A1 (fr) Méthodes et réactifs pour traiter une tumeur et le cancer
US10806793B2 (en) Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
US6852508B1 (en) Chemokine with amino-terminal modifications
US6869606B1 (en) Biotinylated-chemokine antibody complexes
Charles et al. Antibody‐Recruitment as a Therapeutic Strategy: A Brief History and Recent Advances
EP0525570A2 (fr) Anticorps anti-idiotypiques imitant le TNF
JP2003511019A (ja) Ｉｌ１３変異体
US20220280615A1 (en) Immune tolerant elastin-like recombinant peptides and methods of use

Legal Events

Date Code Title Description
FZDE Dead